Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco WilderHill Clean Energy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.76 (market cap $29.60B), while Invesco WilderHill Clean Energy ETF trades at $34.76. The key difference: Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PBW | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $46.99 |
52-Week Low | $205.48 | $24.14 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
PBW trades at $34.93, up 0.92% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF benefits from clean energy tailwinds, including rising global investment and energy security concerns, yet lacks disclosed fundamental ratios. Recent news highlights volatility linked to interest rate movements and sector rotations.
Outlook is mixed: clean energy demand offers growth potential, but sensitivity to Treasury yields and tech sell-offs poses risks. Investors face upside from policy support offset by macroeconomic headwinds and valuation uncertainties due to missing financial data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
